State-of-the-Art Review : Thrombolytic Drugs in Acute Myocardial Infarction

Sutton D. , Young Jwr. A concise textbook of clinical imaging, 2nd ed., St. Louis: Mosby, 1995.

Mruk JS , Zodhelyi P. , Webster Mci. Does antithrombin therapy influence residual thrombus after thrombolysis of platelet rich thrombus? Effects of r-hirudin, heparin or aspirin. Circulation 1996;93:792.

Chesebro JH , Faster V. Dynamic thrombosis and thrombolysis, role of antithrombins. Circulation 1991;83:1815.

White HD , Aylward PE , Frey MJ , et al. On behalf of the hirulog early reperfusion/occlusion (HERO) trial investigators: randomized double-blind comparison of Hirulog vs heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155.

Chesebro JH Direct thrombin inhibition superior to heparin during and after thrombolysis, dose, duration and drug [Editorial]. Circulation 1997;96:2118.

Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures. Guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart association . J Am Coll Cardiol 1990;16:249.

Cummins RO Textbook of advanced cardiac life support. Dallas : American Heart association, 1994 .

Fibrinolytic Therapy Trialists Collaborative Group. Indication for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994;343:311.

National Heart Attack Alert Program Coordinating Committee. 60 minutes to treatment working group. Ann Emerg Med 1994; 23:311.

Paul L. Marino. The ICU book, 2nd ed. Baltimore: Williams & Wilkins, 1998.

Rogers WJ Contemporary management of acute myocardial infarction. Am J Med 1995;99:195.

Gruppo Italiano per lo studio della stretochinasi nell Infarto Miocardico (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397.

ISIS-2, Second International Study of Infarct Survival Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 . Lancet 1988;2:349.

Wilcox RG , von der Lippe G. , Olsson CG , et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Lancet 1988 ;2:525.

ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity and size at 21 days. N Engl J Med 1986;314:1465.

AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988;1:842.

Topol EJ Which thrombolytic agent should we choose? Prog Cardiovasc Dis 1991;34:165.

Fears R. , Ferres H. , Glasgow E. , et al. Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG. Br Heart J 1992; 68:167.

Hoffman JJ , Fears R. , Bonnier JJ , et al. Significance of antibodies to streptokinase in coronary thrombolytic therapy with streptokinase or APSAC.Fibrinolysis 1988;2:203.

Fears R. , Hearn J. , Standring R. , et al. Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicenter patency comparison of intravenous streptokinase and anistreplase in acute myocardial infarction. Am Heart J 1992;124:305.

Jalihal S. , Morris GK Antistreptokinase titres after intravenous streptokinase. Lancet 1990;335:184.

Topol EJ , Morris DC , Smalling RW , et al. A multicenter, randomized, placebo- controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (Activase) in acute myocardial Infarction. J Am Coll Cardiol 1987;91:205.

Anderson JL , Marshall HW , Askins JC , et al. A randomized trial of intravenous and intracoronary streptokinase in patients with acute myocardial infarction.Circulation 1984;70:606.

Anderson JL , Sorensen SG , Moreno FL , et al. Multicenter patency trial of intravenous anistreplase compared with streptokinase in acute myocardial infarction: the TEAM-2 Study Investigators . Circulation 1991;83:126.

Ribeiro E. , Silva LA , Carneiro R. , et al. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol 1993;22:376.

Tierney LM Jr , McPhee SJ , Papadakis MA , eds. Current medical diagnosis & treatment, 38th ed. Stamford, CT: Appleton & Lange, 1999.

Granger CB , Califf RM , Topol EJ Thrombolytic therapy for acute myocardial infarction. A review. Drugs 1992;44:293.

Mathey DG , Schofer J. , Sheehan FH , et al. Intravenous urokinase in acute myocardial infarction. Am J Cardiol 1985;55:878.

Wall TC , Phillips HR , Stack RS , et al. Results of high dose intravenous urokinase for acute myocardial infarction. Am J Cardiol 1990;65:124.

Topol EJ , Califf RM , George BS , et al. Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction (TAMI-2). Circulation 1988;77:1100.

Urokinase and Alteplase in Myocardial Infarction Collaborative Group (URALMI). Combination of urokinase and alteplase in the treatment of myocardial infarction. Coron Artery Dis 1991;2:225.

Califf RM , Topol EJ , Stack RS , et al. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction: results of thrombolysis and angioplasty in myocardial infarction- Phase 5 randomized trial. Circulation 1991;83:1543.

Neuhaus KL , Tebbe U. , Gottwik M. , et al. Intravenous recombinant tissue plasminogen activator (t-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS). J Am Coll Cardiol 1988;12:581.

Whitlow PL , Bashore TM Catheterization/Rescue Angioplasty Following Thrombolysis (CRAFT) Study: Acute myocardial infarction treated with recombinant tissue plasminogen activator versus urokinase [Abstract]. J Am Coll Cardiol 1991;17(Suppl): 276A.

Wall TC , Phillips HR , Stack RS , et al. Results of high dose intravenous urokinase for acute myocardial infarction. Am J Cardiol 1990;65:124.

Mathey DG , Schfer J. , Sheehan FH , et al. Intravenous urokinase in acute myocardial infarction. Am J Cardiol 1985;55:878.

Topol EJ , Bell WR , Weisfeldt ML Coronary thrombolysis with recombinant tissue- type plasminogen activator: a hematologic and pharmacologic study. Ann Intern Med 1985;103:837.

Topol EJ , Ciuffo AA , Pearson TA , et al. Thrombolysis with recombinant tissue-type plasminogen activator in atherosclerotic thrombotic occlusion. J Am Coll Cardiol 1985;5:85.

Neuhaus KL , Feuerer W. , Jeep Tebbe S , et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989;14:1566.

Bassand JP , Machercourt J. , Cassagnes J. , et al. Multicenter trial of intravenous anisoylated plasminogen streptokinase complex (APSAC) in acute myocardial infarction. Effects on infarct size and left ventricular function. J Am Coll Cardiol 1989; 13:988.

Stringer KA Biochemical and pharmacologic comparison of thrombolytic agents. Pharmacotherapy 1996;16(Pt 2):119S.

Koster RW , Collen AF , Hopkins GR , et al. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost 1994 ;72:740.

Cutler D. , Bode C. , Runge MS The promise of new genetically engineered plasminogen activators. J Vasc Interv Radiol 1995;6: 3S.

Sasahara AA , Barker WM , Weaver WD , et al. Clinical studies with the new glycosylated recombinant prourokinase. J Vasc Interv Radiol 1995;6(Suppl):84S.

Spieker M. , Meyer J. Prourokinase fur die Infarkttherapie (prourokinase for treatment of acute myocardial infarction). Herz 1994;19:326.

Tebbe U. , Michels R. , Adgey J. , et al. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS equivalence trial. J Am Coll Cardiol 1998;31:487.

Vermeer F. , Bar F. , Windeler J. , et al. Saruplase, a new fibrin specific thrombolytic agent: final results of the PASS study (1689 patients). Circulation 1993;88:I-292.

Bar FW , Meyer J. , Vermeer F. , et al. for the SESAM Study Group. Comparison of saruplase and alteplase in acute myocardial infarction. Am J Cardiol 1997;79:732.

PRIMI Trial Study Group. Randomized double blind trial of recombinant prourokinase against streptokinase in acute myocardial infarction . Lancet 1989;1:863.

Bode C. , Peter K. , Nordt T. , et al. New developments in thrombolytic therapy.Fibrin Proteol 1997;1(Suppl 1):109.

Bode C. , Runge MS , Schnermark S. , et al. Conjugation to an antifibrin Fab' enhances fibrinolytic potency of single chain urokinase plasminogen activator. Circulation 1990;81:1974.

Ross AM New plasminogen activators. A clinical review. Clin Cardiol 1999;22:165.

Ross AM , Coyne K. , Moreya E. , et al. for the GUSTO-1 Angiographic Investigators. Extended mortality benefit of early post-infarction reperfusion . Circulation 1998;97:1549.

Collen D. Thrombolytic therapy. Thromb Haemost 1997;78:742.

Lefkovits J. , Topol EJ Future directions in thrombolysis for myocardial infarction: what are the unanswered questions? Coron Artery Dis 1994;5:306.

Huber, Maure G. Thrombolytic therapy in acute myocardial infarction . Semin Thromb Hemost 1996;22:15.

Van de Werf F. TNK-t-PA: results of the phase II trials. TIMI 10B and ASSENT-I. Presented at the New Developments in Thrombolytic and Antithrombotic Therapy Satellite Symposium at the XIX Congress of the European Society of Cardiology; August 24-28, 1997; Stockholm, Sweden.

Smalling RW Molecular biology of plasminogen activators: what are the clinical implications of drug design? Am J Cardiol 1996;78(Suppl 12A):2.

The GUSTO-III Investigators. Comparison of reteplase for acute myocardial infarction . N Engl J Med 1997;337:118.

Bode C. , Smalling RW , Berg G. , et al., for the RAPID II Investigators. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891.

White HD Thrombolytic therapy and equivalence trials. J Am Coll Cardiol 1998 ;31:494.

Gurbel PA , Serbruany VL , Shustov AR , et al., for the GUSTO III Investigators. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction Treatment . J Am Coll Cardiol 1998; 31:1466.

Brenner SJ , Topol EJ Third generation thrombolytic agents for acute myocardial infarction . In: Topol EJ , ed. Acute coronary syndromes. New York: Marcel Dekker , 1998:167.

Ogata N. , Ogata Y. , Hokamaki J. , et al. Serial changes of plasminogen activator inhibitor activity in thrombolytic therapy for acute myocardial infarction: comparison between thrombolytic therapies with mutant tPA (Lanoteplase, BMS-200980) and recombinant tPA (alteplase) . Circulation 1996;94(Suppl 1):1.

Thadani V. Lanoteplase: the In Time study. Presented at Myocardial Reperfusion X: Concepts and Controversies: Satellite symposium at the 46th Annual Scientific Session of the American College of Cardiology ; March 14, 1997; Anaheim, California.

Neuhaus KL , van de Werf F. New thrombolytics ease treatment of MI. Modern Medicine 1999;67:49.

McCluskey ER , Keyt BA , Refino CJ , et al. Biochemistry, pharmacology, and initial clinical experience with TNK-tPA. In: Sasahara AA , Loscalzo J , eds. New Therapeutic Agents in Thrombosis and Thrombolysis. New York: Marcel Dekker Inc., 1997 :475.

De Marco E. , Rebuzi AG , Quaranta G. , et al. Lack of procoagulant effect after TNK plasminogen activator in patients with acute myocardial infarction . Eur Heart J 1998;19(Suppl):5.

Ghali M. , Sequeira RF , McKendall GR , et al., and the TIMI 10A Investigators. TNK- tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction. TIMI 10A dose ranging trial . Circulation 1997;95:351.

Cannon C. , McCabe CH , Gibson CM , et al. TNK-t-PA compared with front-loaded tissue plasminogen activator in acute myocardial infarction: primary results of the TIMI 10B trial. Circulation 1997;96(Suppl I):I.

Keyt BA , Paoni NF , Refino CJ , et al. A faster-acting and more potent form of tissue plasminogen activator . Proc Natl Acad Sci U S A 1994;91:3670.

Topol EJ Toward a new frontier in myocardial reperfusion therapy. Emerging platelet preeminence. Circulation 1998;97: 211.

De Marco E. , Rebuzzi AG , Quaranta G. , et al. Lack of procoagulant effect after TNK-plasminogen activator in patients with acute myocardial infarction . Eur Heart J 1998;19(Suppl):5.

Cannon CP , Mc Cabe CH , Gibson CM , et al., and the TIMI 10A investigators. TNK-tPA in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose ranging trial. Circulation 1997;95:351.

The GUSTO Angiographic investigators: The effects of tissue plasminogen activator, streptokinase or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 1993;329:1615.

Smalling RW , Bode C. , Kalbfleisch J. , et al., and the RAPID investigators. More rapid, complete and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995; 91:2725.

Bode C. , Smalling RW , Berg G. , et al., for the RAPID II investigators. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891.

Cannon CP , Mc Cabe CH , Gibson CM , et al. TNK-tPA compared with front-loaded tissue plasminogen activator in acute myocardial infarction: primary results of the TIMI 10B trial. Circulation 1997;96(Suppl):1.

Gibson CM A randomized prospective comparison of tPA with TNK-tPA using the TIMI Frame Count: results of TIMI-10B. Presented at the 70th Scientific sessions of the American Heart Association; November 9-12, 1997; Orlando, Florida.

Gibson CM , Cannon CP , Mc Cabe C. , et al. A randomized prospective comparison of tPA with TNK using the TIMI frame count: Results of the TIMI 10B. Circulation 1997;96(Suppl I):1330.

Van de Werf F. TNK-tPA: results of the phase II trials. TIMI 10B and ASSENT-1. Presented at the New Development in Thrombolytic and Antithrombotic Therapy Satellite symposium at the XIX Congress of the European Society of Cardiology; August 24-28, 1997; Stockholm, Sweden.

Collen D. , Vanderschueren S. , van de Werf F. Fibrin-selective thrombolytic therapy with recombinant staphylokinase . Haemostasis 1996;26(Suppl 4):294.

Bode C. , Peter K. , Nordt T. , et al. New developments in thrombolytic therapy. Fibrin Proteol 1997;11(Suppl 1):109.

Anderschueren S. , Barrios L. , Kerssinchai P. , et al., for the STAR Trial Group. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction . Circulation 1995;92:2044.

Sako T. , Tsuchida N. Nucleotide sequence of the streptokinase gene from staphylococcus aureus. Nucleic Acids Res 1983;11: 7679.

Behnke D. , Gerlach D. Cloning and expression in Escherichia coli, Bacilus subtilis and streptococcus sanguis of a gene for staphylokinase: a bacterial plasminogen activator. Mol Gen Genet 1987;210:528.

Collen D. , Zhao ZA , Holvoet P. , et al. Primary structure and gene structure of staphylokinase. Fibrinolysis 1992;6:226.

Schlott B. , Hartman M. , Guhrs KM , et al. The thermostability of natural variants of bacterial plasminogen-activator staphylokinase. Eur J Biochem 1994;223:303.

Collen D. , Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 1993;87:1850.

Vanderschueren S. , Collen D. , Van de Werf F. Coronary reperfusion in patients with an acute myocardial infarction following intravenous administration of recombinant staphylokinase [Abstract]. J Am Coll Cardiol 1994;23:315A.

Collen DC , Gold HK New developments in thrombolytic therapy. Thromb Res 1990;(Suppl X):105.

Gulba DC , Bode C. , Runge MS , et al. Thrombolytic agents - an overview. Ann Hematol 1996;73(Suppl I):59.

Lerakis S. , Stoufer GA , Runge MS New thrombolytics: what is under development? Biodrugs 1997;8:24.

Collen D. Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent . Nat Med 1998;4:279.

Gardel SJ , Ramjit DR , Stabilino II , et al. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 1991;84:244.

Mellott MJ , Stabilino II , Holahan M. , et al. Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. Arterioscler Thromb 1992;12:212.

Kingston IB , Castro Mjm , Anderson S. In vitro stimulation of tissue-type plasminogen activator by Alzheimer amyloid β-peptide analogues . Nat Med 1995;1:138.

Brodie BR , Stone GW , Morice MC , et al. Importance of time to reperfusion on outcomes after primary PTCA for acute myocardial infarction: results from stent PAMI [Abstract]. J Am Coll Cardiol 1999;33(Suppl A):353A.

Zeyer U. , Schroder R. , Molhoek P. , et al., for the HIT-4 Investigators. Noninvasive assessment of infarct-related artery patency after thrombolysis for acute myocardial infarction by ST resolution: results of the HIT-4 angiographic substudy [Abstract]. J Am Coll Cardiol 1999 ;33(Suppl A):324A.

Hudson MP , Granger CB , Pieper KS , et al. Reinfarction after thrombolytic therapy: experience from the GUSTO-1 and III Trials [Abstract]. J Am Coll Cardiol 1999;33(Suppl A):130.

Kostis JB , Liao WC , Beierle FA , et al. Single bolus regimen of lanoteplase (nPA) in acute myocardial infarction: hemostatic evaluation vs. he In Time Study [Abstract]. J Am Coll Cardiol 1999;2(Suppl A):131.

Owen J. , Friedman KD , Grossman BA , et al. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988;72:616.

Bleich SD , Nichols TC , Schumacher RR , et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:1412.

Hsia J. , Hamilton WP , Kleiman N. et al., for the Heparin-Aspirin Reperfusion Trial (HART) investigators: a comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323:1433.

De Bono DP , Simoons ML , Tijssen J. , et al., for the European Cooperative study Group (ECSG). Effect of early intravenous heparin on coronary patency, infarct size and bleeding complications after alteplase thrombolysis: results of a randomized boubleblind European Cooperative Study Group Trial. Br Heart J 1992:67:1212.

Special report on reperfusion in acute myocardial infarction of the International Society and Federation of Cardiology and World Health Organization Task Force on Myocardial reperfusion. Circulation 1994;90:2091.

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 . Lancet 1988:2:349.

The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 1993;329:1615.

Verstraete M. , Zoldhelyi P. Novel antithrombotic drugs in development . Drugs 1995;49:856.

Weitz JI , Califf RM , Ginsberg JS , et al. New antithrombotics. Chest 1995 ;108:4715.

Lijnen HR , Collen D. Experimental studies in thrombolysis and fibrinolysis. Curr Opin Cardiol 1993:8:613.

Coller BS The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb/IIIa receptors as antithrombotic therapy. Eur Heart J 1995; 16(Suppl L):11.

Jang IK , Fuster V. , Gold HK Antiplatelet agents. Coron Artery Dis 1992 ;3:1030.

Kleiman NS , Ohman EM , Califf RM , et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the TAMI 8 Pilot study. J Am Coll Cardiol 1993 :22:381.

The GUSTO Investigators. An International randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673.

Neuhaus KL , von Essen R. , Tebbe U. , et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausartze (ALKK). Circulation 1994;90:1638.

Global Use of Strategies to Open Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes . Circulation 1994;90:1631.

Antman EM , for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994;90:1624.

Ohman EM , Califf Rm , Topol EJ , et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990;82:781.

Bode C. , Hudelmayer M. , Mehwald P. , et al. Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin. Circulation 1994;90: 1956.

Loayza SL , Trikha M. , Markland FS , et al. Resolution of isoforms of natural and recombinant fibrolase, the fibrinolytic enzyme from Agkistrodon contortrix snake venom, and comparison of their EDTA sensitivities. J Chromatgr Biomed Appl 1994;662: 227.

Markland FS , Friedrichs GS , Pewitt SR , et al. Thrombolytic effects of recombinant fibrolase or APSAC in a canine model of carotid artery thrombosis. Circulation 1994;90:2448.

Chesebro JH , Badimon JJ Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease. N Engl J Med 1998;338: 1539.

Iqbal O. New anticoagulants for adjunct use in angiography. In: Pifarre R , ed. New anticoagulants for the cardiovascular patient. Philadelphia: Hanley & Belfus, Inc., 1997:471.

Iqbal O. Thrombolytic drugs offer new therapeutic options. Diagnostic Imaging 1998;79:59.

Wehrmacher WH Anticoagulants in myocardial infarction. Am J Cardiol 1958;2:646.

Wehrmacher WH Myocardial infarction patterns, ch 14 (13 slides) . In: Clinical electrocardiography [slide]. Edited by James WE , Wolf PS , Tucker CE. Parker, CO: Post-graduate Institute for Medicine, 1981.

Messmore HL , Wehrmacher WH Therapeutic use of low molecular weight heparins . Semin Thromb Hemost 1993 ;19(Suppl 1):97.

Wehrmacher WH , Moncada R. , Fareed J. , et al. Studies on the intravascular contrast media induced release of tissue plasminogen activator: Implications on the hemostatic processes. Federation Proceedings 1985;44:4.

Schnee JM , Runge MS , Matsueda GR , et al. Construction and expression of a recombinant antibody-targeted plasminogen activator. Proc Natl Acad Sci U S A 1987;84:6904.